Skip to content

Author

Rachel Hazlitt

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Aug 2026

Safety reporting in chronic kidney disease clinical trials: a comparison of ClinicalTrials.gov registries and published reports

Transparent reporting of adverse events (AEs) is essential for evaluating the safety of interventions from chronic kidney disease (CKD), a population especially vulnerable to treatment-related harm because of polypharmacy, reduced renal clearance, and high comorbidity burden. Since 2007, the FDA Amendments Act (FDAAA 8...

Nevada Denton, Lydia Hashemi, Daniel Archer et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.